tetano
Editor, Senior Moderator
J Glob Infect Dis
. 2021 Jan 29;13(1):38-41.
doi: 10.4103/jgid.jgid_180_20. eCollection Jan-Mar 2021.
Persistent Hypercoagulable State in COVID-19: A Case Series of COVID-19 Associated Pulmonary Embolism
Kok Hoe Chan[SUP] 1 [/SUP], Su Lin Lim[SUP] 1 [/SUP], Hamid Shaaban[SUP] 1 2 [/SUP], Gunwant Guron[SUP] 1 2 [/SUP], Jihad Slim[SUP] 1 3 [/SUP]
Affiliations
Abstract
Coronavirus disease 2019 (COVID-19) has swept through the world with millions of cases and hundreds of thousands of deaths. COVID-19-associated coagulopathy has been recognized as the major cause of morbidity and mortality. To the best of our knowledge, a majority of the cases of coagulopathy have been reported in patients with moderate-to-severe COVID-19 and limited to observations during the recovery/postcytokine storm state. Herein, we report a case series of two patients with COVID-19 who developed pulmonary embolism in the late phase of the disease. This raised the hypothesis that the risk of hypercoagulability in patients with COVID-19 can persist until the recovery phase, which would warrant a follow-up with D-dimer and fibrinogen trending, as well as postdischarge thromboprophylaxis for at least 2 weeks during the recovery phase.
Keywords: Anticoagulation; coronavirus disease 2019; hypercoagulable; pulmonary embolism; severe acute respiratory syndrome coronavirus 2.
. 2021 Jan 29;13(1):38-41.
doi: 10.4103/jgid.jgid_180_20. eCollection Jan-Mar 2021.
Persistent Hypercoagulable State in COVID-19: A Case Series of COVID-19 Associated Pulmonary Embolism
Kok Hoe Chan[SUP] 1 [/SUP], Su Lin Lim[SUP] 1 [/SUP], Hamid Shaaban[SUP] 1 2 [/SUP], Gunwant Guron[SUP] 1 2 [/SUP], Jihad Slim[SUP] 1 3 [/SUP]
Affiliations
- PMID: 33911452
- PMCID: PMC8054785
- DOI: 10.4103/jgid.jgid_180_20
Abstract
Coronavirus disease 2019 (COVID-19) has swept through the world with millions of cases and hundreds of thousands of deaths. COVID-19-associated coagulopathy has been recognized as the major cause of morbidity and mortality. To the best of our knowledge, a majority of the cases of coagulopathy have been reported in patients with moderate-to-severe COVID-19 and limited to observations during the recovery/postcytokine storm state. Herein, we report a case series of two patients with COVID-19 who developed pulmonary embolism in the late phase of the disease. This raised the hypothesis that the risk of hypercoagulability in patients with COVID-19 can persist until the recovery phase, which would warrant a follow-up with D-dimer and fibrinogen trending, as well as postdischarge thromboprophylaxis for at least 2 weeks during the recovery phase.
Keywords: Anticoagulation; coronavirus disease 2019; hypercoagulable; pulmonary embolism; severe acute respiratory syndrome coronavirus 2.